19 analysts have expressed a variety of opinions on AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 8 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 5 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 3 | 0 | 0 |
| 3M Ago | 2 | 1 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $210.89, a high estimate of $231.00, and a low estimate of $191.00. This upward trend is evident, with the current average reflecting a 2.24% increase from the previous average price target of $206.27.
Exploring Analyst Ratings: An In-Depth Overview
The standing of AbbVie among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tim Anderson | B of A Securities | Announces | Neutral | $191.00 | - |
| David Risinger | Leerink Partners | Announces | Outperform | $206.00 | - |
| Alexandria Hammond | Wolfe Research | Announces | Outperform | $205.00 | - |
| Chris Schott | JP Morgan | Lowers | Overweight | $200.00 | $210.00 |
| Geoff Meacham | Citigroup | Lowers | Buy | $215.00 | $226.00 |
| Evan David Seigerman | BMO Capital | Lowers | Outperform | $208.00 | $228.00 |
| Terence Flynn | Morgan Stanley | Lowers | Overweight | $224.00 | $231.00 |
| Vamil Divan | Guggenheim | Raises | Buy | $221.00 | $212.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $226.00 | $215.00 |
| Navin Jacob | UBS | Raises | Neutral | $200.00 | $195.00 |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $231.00 | $218.00 |
| Andrew Baum | Citigroup | Raises | Buy | $215.00 | $170.00 |
| Geoff Meacham | B of A Securities | Raises | Neutral | $195.00 | $185.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $220.00 | $214.00 |
| Aaron Gal | Bernstein | Announces | Market Perform | $203.00 | - |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $215.00 | $210.00 |
| Navin Jacob | UBS | Raises | Neutral | $195.00 | $185.00 |
| Carter Gould | Barclays | Raises | Overweight | $212.00 | $200.00 |
| Steve Scala | TD Cowen | Raises | Buy | $225.00 | $195.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AbbVie compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AbbVie's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on AbbVie analyst ratings.
Discovering AbbVie: A Closer Look
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Understanding the Numbers: AbbVie's Finances
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: AbbVie's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.83%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.73% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): AbbVie's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 11.78, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
